President Donald Trump has introduced a new policy aimed at dramatically reducing prescription drug prices in the United States, claiming that the new measure could lead to savings between 30 and 80 percent.
The announcement was made Sunday in a social media post, where Trump outlined his administration’s latest effort to make medications more affordable for Americans.
“They will rise throughout the World in order to equalize and, for the first time in many years, bring FAIRNESS TO AMERICA!” Trump declared in the post. He added that he planned to authorize the measure through an executive order, which he intended to sign at 9:00 am (1300 GMT) on Monday.
At the core of the policy is a “MOST FAVORED NATION’S” clause, which would link the cost of prescription drugs in the US to the lowest price paid by any other country for the same medication. Trump emphasized that while the prices Americans pay would decrease, the costs in other parts of the world would likely increase to balance out the adjustment.
The “most favored nation” concept originates from a rule within the World Trade Organization that seeks to ensure non-discriminatory practices among trading partners. The principle is meant to level the playing field in international commerce, preventing any country from receiving less favorable terms than others.
Although Trump presented this new plan with enthusiasm, the White House has not yet released further details, despite a request for clarification from AFP.
This isn’t Trump’s first attempt to tackle high drug prices. During his previous tenure from 2017 to 2021, he announced a similar policy aimed at lowering prescription costs, but those efforts were ultimately blocked due to strong resistance from the pharmaceutical sector.
Just last month, Trump signed another executive order aimed at easing the burden of drug prices on American citizens. That directive provided states with greater flexibility to source medications from overseas and sought to refine the overall process for negotiating drug prices.
What you should know
President Donald Trump’s latest pharmaceutical policy proposal, which aims to implement a “most favored nation” clause, represents a bold strategy to address one of America’s most persistent healthcare challenges—rising drug prices.
Under this framework, the cost of medications in the United States would be pegged to the lowest prices paid internationally, potentially leading to significant savings for American consumers.
However, the policy could also result in price increases in other countries, creating ripple effects across the global healthcare market.
While the idea of linking domestic drug prices to global benchmarks has gained some public support, it is likely to encounter strong opposition from pharmaceutical companies and trade partners alike.
This move follows Trump’s earlier efforts during his first term, which faced setbacks due to industry lobbying and regulatory hurdles. His recent executive order giving states more autonomy to purchase drugs abroad signals a continued focus on reducing healthcare costs through executive action rather than legislative reform.
Critics argue that such policies, while aggressive, may lack the necessary detail and enforcement mechanisms to be effective.
With no additional information yet released by the White House, it remains uncertain how or when the plan will be implemented and what long-term impact it may have on both the U.S. healthcare system and international drug pricing norms.
ALSO READ TOP STORIES FROM VERILY NEWS
